Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias

作者：T. Badar, Ludovica Marando, Eric Latorre-Crespo, T. Lasho, Francyess Denis Oliva, Chenyu Lin, B. J. McCormick, Mobachir El Kettani, Kashish J. Shah, Yael N Kusne, Omer H Jamy, Kendall Diebold, Alexander Coltoff, C. Finke, James M. Foran, M. Kharfan-Dabaja, Yao-Shan Fan, Liuyan Jiang, Rong He, Miles Thomas, A. Patel, D. Viswanatha, M. Shah, Antoine N. Saliba, A. Mangaonkar, Kristina Kirschner, A. Al-Kali, N. Gangat, M. Litzow, Mirinal S Patnaik · 发表于：Blood Advances · 年份：2026 · DOI：10.1182/bloodadvances.2025018031 · 被引用次数：4 · 研究领域：Medicine

Key Points • PPM1D mutations dominate t-CH/t-CCUS, show the shortest latency after genotoxic therapy, and are enriched in this subgroup.• Although the median PPM1D VAF was relatively lower, a higher VAF (≥13%) was linked to inferior overall survival.